Viewing Study NCT00002268


Ignite Creation Date: 2025-12-24 @ 5:55 PM
Ignite Modification Date: 2025-12-27 @ 6:09 AM
Study NCT ID: NCT00002268
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 1999-11-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
Sponsor: Sandoz
Organization:

Key Dates - Follows AllAPIJSON File Order

Start Date: None
Start Date Type: None
Primary Completion Date: None
Primary Completion Date Type: None
Completion Date: None
Completion Date Type: None
First Submit Date: 1999-11-02
First Submit QC Date: None
Study First Post Date: 2001-08-31
Study First Post Date Type: ESTIMATED
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2005-06-23
Last Update Post Date: 2005-06-24
Last Update Post Date Type: ESTIMATED